# Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

> **NCT01673282** · — · COMPLETED · sponsor: **UCB Pharma GmbH** · enrollment: 315 (actual)

## Conditions studied

- Focal Epilepsy With and Without Secondary Generalization

## Interventions

- **DRUG:** Lacosamide

## Key facts

- **NCT ID:** NCT01673282
- **Lead sponsor:** UCB Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2016-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01673282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01673282, "Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01673282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*